Information  X 
Enter a valid email address

EPIC/TIDM matching '0L8L'

Date
Time Source
Company
Announcement
30 Oct 2018 11:30 am GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
21 Sep 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
  12:17 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
03 Aug 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
31 Jul 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
22 May 2018 7:00 am GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
01 May 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
23 Feb 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Participate in Multiple Conferences in March
13 Feb 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
05 Feb 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Participate in Multiple Conferences in February
24 Jan 2018 9:00 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
04 Jan 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
02 Jan 2018 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics to Participate in Multiple Conferences in January
19 Dec 2017 8:13 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) FDA Approves Spark Therapeutics' LUXTURNA(TM) (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
31 Jul 2017 12:30 pm GNW Factsheet Spark Therapeutics, Inc. (0L8L) Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA(TM) (voretigene neparvovec)


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t